Trials / Conditions / Minimal Change Disease

Minimal Change Disease

22 registered clinical trials studyying Minimal Change Disease — 11 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of WAL0921 in Patients With Glomerular Kidney Diseases NCT06466135	Walden Biosciences	Phase 2
Not Yet Recruiting	Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD NCT06405100	Air Force Military Medical University, China	Phase 3
Not Yet Recruiting	Circulating Factors in Nephrotic Syndrome NCT06315504	Iain Bressendorff	—
Recruiting	taVNS for FRNS in Children NCT05588063	Northwell Health	N/A
Recruiting	Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Diseas NCT05650619	University of Michigan	—
Recruiting	A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) NCT05583942	Northwell Health	N/A
Terminated	Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclero NCT05441826	Tenet Medicines	Phase 2
Recruiting	NEPTUNE Match Study NCT04571658	University of Michigan	N/A
Recruiting	Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome. NCT05505500	University of Michigan	—
Recruiting	Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases NCT05003986	Travere Therapeutics, Inc.	Phase 2
Terminated	A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment NCT04235621	Goldfinch Bio, Inc.	—
Completed	Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change NCT04009668	University of Michigan	Phase 2
Completed	Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease NCT04369183	Istanbul University	—
Recruiting	KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis NCT03929887	Seoul National University Hospital	—
Unknown	Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome NCT03298698	Radboud University Medical Center	Phase 3
Completed	Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy NCT03210688	University of Aarhus	Phase 4
Recruiting	The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) NCT03949972	Prof. Dr. Paul Brinkkoetter	—
Unknown	Diagnostic Value of Linked Color Imaging for Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and G NCT03068572	Affiliated Hospital to Academy of Military Medical Sciences	—
Unknown	Valproic Acid for Idiopathic Nephrotic Syndrome NCT02896270	Universitair Ziekenhuis Brussel	Phase 2 / Phase 3
Completed	Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Exc NCT02592798	Bristol-Myers Squibb	Phase 2
Completed	Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Cha NCT01084980	Seoul National University Hospital	Phase 2 / Phase 3
Completed	Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease NCT00982072	Imperial College Healthcare NHS Trust	Phase 4